Currently Viewing:
Newsroom
Currently Reading
Bone Marrow Environment in Patients With RA May Promote Inflammation
December 12, 2017 – Kelly Davio
Researchers Say Medicare Advantage Plans Need Better Incentives to Meet Future Demand
December 12, 2017 – Allison Inserro
University, Genetics Firm Find Link Between ADHD, Delay Discounting
December 12, 2017 – Allison Inserro
Welltok Identifies Who's at Risk for Getting and Spreading the Flu
December 12, 2017 – Jaime Rosenberg
What We're Reading: Medical Device Approval; Medical Laboratories Sue Government; ACA Sign-Up Deadline
December 12, 2017 – AJMC Staff
What's the Magic Payment Mix for Medicare Primary Care Providers?
December 11, 2017 – Allison Inserro
Racial Disparities Prevalent in Survival of Patients With Ovarian, Colon, and Breast Cancer
December 11, 2017 – Jaime Rosenberg
Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval
December 11, 2017 – Mary Caffrey
The Past, Present, and Future of HIV Funding
December 11, 2017 – Jaime Rosenberg

What We're Reading: Uterine Transplant Birth; Opioid Treatment; Curbing HIV

AJMC Staff
A woman gives birth after receivng a uterine transplant for the first time in the US; a once-monthly treatment for patients with poioid addiction gains FDA approval; and LA public health officials launch an initiative to reduce the annual number HIV infections.

First Baby Born in United States After Uterine Transplant

For the first time in the United States, a woman has delivered a baby following a uterine transplant, reported The New York Times. The mother, who was born without a uterus, received the transplant last year from a living donor at the Baylor University Medical Center in Dallas. The transplants are temporary, allowing a woman to have 1 or 2 children, and then are removed. Until now, all other births following uterine transplant occurred in Sweden, at the Sahlgrenska University Hospital in Gothenburg.



Once-Monthly Opioid Addiction Injection Gains US Approval

The first monthly treatment for addiction to opiates, Indivior Plc’s Sublocade, has been approved by the FDA, according to Bloomberg. The treatment is an injection of buprenorphine, a drug that weakens withdrawal symptoms in patients with addiction. Its infrequent dosing could help patients better adhere to the regimen compared with current treatments, said the FDA. The treatment will be available early next year, according to Indivior.



Los Angeles Officials Initiate Efforts to Curb HIV

With more than 600,000 people living with HIV in the county, Los Angeles public health officials have launched an effort to reduce the annual number of HIV infections, according to The Los Angeles Times. The officials have set their focus on reducing the annual HIV infections, increasing the proportion of people with HIV who are diagnosed, and increasing the proportion of the population who are virally suppressed. They plan to accomplish these goals through encouraging community health centers and private medical providers to focus on preventive care.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!